Cortechs.ai has integrated its AI portfolio into the deepcOS radiology platform.
The integration marks the first outside Cortechs.ai’s ecosystem, according to the firm, and will enable broader access to the company's NeuroQuant, NeuroQuant MS, NeuroQuant Brain Tumor, and OnQ Prostate software, including in Europe.
Cortechs.ai's AI software is designed to assess neurological disorders such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, tumors, and other brain abnormalities.
NeuroQuant and NeuroQuant MS provide automated brain segmentation and volumetric analysis that aid in the early detection and monitoring of neurodegenerative diseases, such as Alzheimer’s disease and multiple sclerosis, according to the firm.
NeuroQuant Brain Tumor provides quantitative imaging analysis to assist clinicians in evaluating brain tumor progression. OnQ Prostate enhances prostate MRI interpretation in the detection and assessment of prostate cancer, according to the vendor.
Integration of Cortechs.ai’s offerings into deepcOS, a vendor-neutral and enterprise-grade AI platform, allows hospitals and radiology centers to deploy advanced imaging applications that support early detection, improved diagnosis, and monitoring of neurological diseases and cancer, Cortechs.ai said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
